Sugi Predict

Sugi Predict / Compounds / SCHEMBL12985331

SCHEMBL12985331

SCHEMBL12985331

O=C(O)C(CO)c1ccc(Cl)cc1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ POLB P06746 2/20 0.56
▸ KMT2A Q03164 4/20 0.54
▸ CYP2C9 P11712 5/20 0.51
▸ CYP2C19 P33261 4/20 0.51
▸ MEN1 O00255 3/20 0.51
▸ CYP2D6 P10635 2/20 0.51
▸ GABBR2 O75899 3/20 0.46
▸ GABBR1 Q9UBS5 3/20 0.46
▸ LMNA P02545 2/20 0.46
▸ CYP3A4 P08684 1/20 0.46
▸ ADORA3 P0DMS8 1/20 0.46
▸ NFKB1 P19838 1/20 0.46
▸ DRD3 P35462 1/20 0.46
▸ BLM P54132 1/20 0.46
▸ CYP1A2 P05177 1/20 0.46
▸ THRB P10828 1/20 0.46
▸ TSHR P16473 1/20 0.46
▸ HSD17B10 Q99714 2/20 0.42
▸ BRD4 O60885 1/20 0.42
▸ HDAC4 P56524 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27805223 0.85 CYP2C9 (0.45) POLBKMT2ACYP2C9CYP2C19MEN1
SCHEMBL9231726 0.83 POLB (0.56) POLBKMT2ACYP2C9CYP2C19MEN1
SCHEMBL1742115 0.82 POLB (0.58) POLBKMT2ACYP2C9CYP2C19MEN1
SCHEMBL31344403 0.82 GABBR2 (0.58) POLBKMT2ACYP2C9CYP2C19MEN1
SCHEMBL28233461 0.82 BRD4 (0.55) POLBKMT2ACYP2C9CYP2C19MEN1
SCHEMBL7711076 0.82 POLB (0.58) POLBKMT2ACYP2C9CYP2C19MEN1
SCHEMBL7899623 0.82 CYP2C9 (0.64) POLBKMT2ACYP2C9CYP2C19MEN1
SCHEMBL5860866 0.82 GABBR2 (0.58) POLBKMT2ACYP2C9CYP2C19MEN1
SCHEMBL16075922 0.82 POLB (0.58) POLBKMT2ACYP2C9CYP2C19MEN1
SCHEMBL25293414 0.81 PTGS1 (0.44) POLBKMT2ACYP2C9CYP2C19MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4721737-A1 USE OF PHARMACEUTICAL COMPOSITION COMPRISING COMPOUND HAVING BIS(AZANYLYLIDENE) SULFONYL STRUCTURE FOR TREATING ANEMIA-RELATED DISEASES Scinnohub Pharmaceutical Co., Ltd. (CN) 2026-04-08 — — EP disclosed
US-20250145635-A1 COMPOUND CONTAINING BIS(AZANYLYLIDENE) SULFONYL STRUCTURE AND USE THEREOF IN MEDICINE SCINNOHUB PHARMACEUTICAL CO., LTD. (CN) 2025-05-08 — — US disclosed
WO-2024245143-A1 USE OF PHARMACEUTICAL COMPOSITION COMPRISING COMPOUND HAVING BIS(AZANYLYLIDENE) SULFONYL STRUCTURE FOR TREATING ANEMIA-RELATED DISEASES 赛诺哈勃药业（成都）有限公司 2024-12-05 — — WO disclosed
EP-4455136-A1 COMPOUND CONTAINING BIS(AZANYLYLIDENE) SULFONYL STRUCTURE AND USE THEREOF IN MEDICINE Scinnohub Pharmaceutical Co., Ltd. (CN) 2024-10-30 — — EP disclosed
CN-118510768-A Diazasulfinyl structure-containing compounds and their use in medicine 赛诺哈勃药业（成都）有限公司 2024-08-16 — — CN disclosed
WO-2023116774-A1 COMPOUND CONTAINING BIS(AZANYLYLIDENE) SULFONYL STRUCTURE AND USE THEREOF IN MEDICINE 赛诺哈勃药业（成都）有限公司 2023-06-29 — — WO disclosed
WO-2023116774-A1 COMPOUND CONTAINING BIS(AZANYLYLIDENE) SULFONYL STRUCTURE AND USE THEREOF IN MEDICINE 赛诺哈勃药业（成都）有限公司 2023-06-29 — — WO disclosed
EP-2694509-B1 PYRROLO[2,3-D]PYRIMIDINE DERIVATIVES AS INHIBITORS OF TROPOMYOSIN-RELATED KINASES PFIZER LTD (GB) 2016-05-18 — — EP disclosed
EP-2694509-B1 PYRROLO[2,3-D]PYRIMIDINE DERIVATIVES AS INHIBITORS OF TROPOMYOSIN-RELATED KINASES PFIZER LTD (GB) 2016-05-18 — — EP disclosed
US-20140364415-A1 PYRROLO[2,3-d]PYRIMIDINE TROPOMYSIN-RELATED KINASE INHIBITORS PFIZER LIMITED (GB) 2014-12-11 — — US disclosed
US-20140364415-A1 PYRROLO[2,3-d]PYRIMIDINE TROPOMYSIN-RELATED KINASE INHIBITORS PFIZER LIMITED (GB) 2014-12-11 — — US disclosed
US-20140364415-A1 PYRROLO[2,3-d]PYRIMIDINE TROPOMYSIN-RELATED KINASE INHIBITORS PFIZER LIMITED (GB) 2014-12-11 — — US disclosed
US-8846698-B2 Pyrrolo[2,3-d]pyrimidine tropomysin-related kinase inhibitors PFIZER LIMITED (US) 2014-09-30 — — US disclosed
US-8846698-B2 Pyrrolo[2,3-d]pyrimidine tropomysin-related kinase inhibitors PFIZER LIMITED (US) 2014-09-30 — — US disclosed
US-8846698-B2 Pyrrolo[2,3-d]pyrimidine tropomysin-related kinase inhibitors PFIZER LIMITED (US) 2014-09-30 — — US disclosed
EP-2694509-A1 PYRROLO [2, 3 -D]PYRIMIDINE DERIVATIVES AS INHIBITORS OF TROPOMYOSIN- RELATED KINASES Pfizer Limited (GB) 2014-02-12 — — EP disclosed
US-20120258950-A1 PYRROLO[2,3-d]PYRIMIDINE TROPOMYSIN-RELATED KINASE INHIBITORS PFIZER LIMITED (GB) 2012-10-11 — — US disclosed
US-20120258950-A1 PYRROLO[2,3-d]PYRIMIDINE TROPOMYSIN-RELATED KINASE INHIBITORS PFIZER LIMITED (GB) 2012-10-11 — — US disclosed
WO-2012137089-A1 PYRROLO [2, 3 -D] PYRIMIDINE DERIVATIVES AS INHIBITORS OF TROPOMYOSIN- RELATED KINASES PFIZER LIMITED (GB) 2012-10-11 — — WO disclosed
US-20120258950-A1 PYRROLO[2,3-d]PYRIMIDINE TROPOMYSIN-RELATED KINASE INHIBITORS PFIZER LIMITED (GB) 2012-10-11 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250145635-A1 COMPOUND CONTAINING BIS(AZANYLYLIDENE) SULFONYL STRUCTURE AND USE THEREOF IN MEDICINE BCL9, USP9X, BCL9L POLB 3832/4885KMT2A 646/4885CYP2C9 1519/4885
US-20140364415-A1 PYRROLO[2,3-d]PYRIMIDINE TROPOMYSIN-RELATED KINASE INHIBITORS DMPK, DTYMK, MUSK POLB 1288/4885KMT2A 2918/4885CYP2C9 3689/4885
US-20120258950-A1 PYRROLO[2,3-d]PYRIMIDINE TROPOMYSIN-RELATED KINASE INHIBITORS DMPK, DTYMK, MUSK POLB 1288/4885KMT2A 2918/4885CYP2C9 3689/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.